Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 40 | 2025 | 201 | 11.640 |
Why?
|
| Infant, Very Low Birth Weight | 34 | 2022 | 188 | 8.270 |
Why?
|
| Intensive Care Units, Neonatal | 36 | 2025 | 210 | 7.300 |
Why?
|
| Breast Feeding | 31 | 2025 | 170 | 6.690 |
Why?
|
| Mothers | 23 | 2025 | 193 | 5.460 |
Why?
|
| Infant, Premature | 35 | 2025 | 219 | 4.660 |
Why?
|
| Infant, Newborn | 56 | 2025 | 656 | 4.370 |
Why?
|
| Enterocolitis, Necrotizing | 13 | 2022 | 49 | 3.070 |
Why?
|
| Lactation | 11 | 2021 | 62 | 2.510 |
Why?
|
| Infant Nutritional Physiological Phenomena | 15 | 2025 | 80 | 2.370 |
Why?
|
| Infant | 25 | 2025 | 591 | 2.310 |
Why?
|
| Patient Discharge | 9 | 2025 | 162 | 2.200 |
Why?
|
| Milk Banks | 4 | 2020 | 22 | 1.890 |
Why?
|
| Gestational Age | 12 | 2025 | 87 | 1.870 |
Why?
|
| Enteral Nutrition | 5 | 2022 | 65 | 1.760 |
Why?
|
| Infant Formula | 4 | 2020 | 22 | 1.420 |
Why?
|
| Child Development | 4 | 2020 | 75 | 1.410 |
Why?
|
| Infant, Premature, Diseases | 4 | 2020 | 31 | 1.350 |
Why?
|
| Female | 48 | 2025 | 15793 | 1.330 |
Why?
|
| Intensive Care, Neonatal | 7 | 2020 | 37 | 1.330 |
Why?
|
| Humans | 59 | 2025 | 28462 | 1.190 |
Why?
|
| Social Support | 3 | 2019 | 216 | 1.170 |
Why?
|
| Breast Milk Expression | 9 | 2020 | 42 | 1.130 |
Why?
|
| Residence Characteristics | 2 | 2019 | 216 | 1.050 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 311 | 0.900 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2020 | 15 | 0.840 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 87 | 0.820 |
Why?
|
| Goals | 3 | 2017 | 44 | 0.790 |
Why?
|
| Retrospective Studies | 13 | 2025 | 3612 | 0.760 |
Why?
|
| Prospective Studies | 13 | 2021 | 1810 | 0.740 |
Why?
|
| Pregnancy | 5 | 2025 | 340 | 0.740 |
Why?
|
| Bronchopulmonary Dysplasia | 3 | 2016 | 18 | 0.740 |
Why?
|
| Vitamin D | 1 | 2021 | 41 | 0.730 |
Why?
|
| Infant, Low Birth Weight | 2 | 2019 | 18 | 0.720 |
Why?
|
| Health Care Costs | 3 | 2020 | 80 | 0.710 |
Why?
|
| Neonatology | 1 | 2020 | 4 | 0.710 |
Why?
|
| Birth Weight | 7 | 2022 | 46 | 0.700 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 33 | 0.690 |
Why?
|
| Gastroschisis | 1 | 2020 | 4 | 0.680 |
Why?
|
| Male | 28 | 2025 | 15367 | 0.670 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 11 | 0.660 |
Why?
|
| United States | 7 | 2025 | 2185 | 0.660 |
Why?
|
| Diet | 3 | 2022 | 221 | 0.650 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 52 | 0.630 |
Why?
|
| Aftercare | 1 | 2018 | 26 | 0.610 |
Why?
|
| Anxiety | 1 | 2019 | 161 | 0.600 |
Why?
|
| Hospitalization | 4 | 2018 | 322 | 0.600 |
Why?
|
| Oxidative Stress | 1 | 2018 | 107 | 0.580 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 82 | 0.570 |
Why?
|
| Nervous System | 1 | 2017 | 10 | 0.570 |
Why?
|
| Maternal Behavior | 1 | 2017 | 11 | 0.560 |
Why?
|
| Stress, Psychological | 1 | 2019 | 243 | 0.560 |
Why?
|
| Pregnancy in Adolescence | 1 | 2017 | 13 | 0.560 |
Why?
|
| Educational Status | 5 | 2019 | 298 | 0.530 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 232 | 0.520 |
Why?
|
| Adult | 14 | 2025 | 8152 | 0.520 |
Why?
|
| Quality of Health Care | 1 | 2017 | 126 | 0.510 |
Why?
|
| Quality Improvement | 1 | 2017 | 161 | 0.500 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 53 | 0.500 |
Why?
|
| Bacteria | 1 | 2016 | 76 | 0.500 |
Why?
|
| Depression | 1 | 2019 | 454 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 186 | 0.480 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 184 | 0.430 |
Why?
|
| Postpartum Period | 3 | 2021 | 24 | 0.380 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 939 | 0.340 |
Why?
|
| Nutritive Value | 2 | 2020 | 24 | 0.320 |
Why?
|
| Nutritional Status | 2 | 2020 | 60 | 0.320 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2017 | 22 | 0.310 |
Why?
|
| Cohort Studies | 8 | 2022 | 1948 | 0.270 |
Why?
|
| Child Language | 2 | 2017 | 19 | 0.270 |
Why?
|
| Age Factors | 2 | 2020 | 793 | 0.270 |
Why?
|
| Incidence | 7 | 2020 | 779 | 0.260 |
Why?
|
| Infant, Extremely Premature | 2 | 2022 | 11 | 0.260 |
Why?
|
| Bottle Feeding | 2 | 2016 | 16 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 376 | 0.250 |
Why?
|
| Anthropometry | 1 | 2005 | 36 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 285 | 0.240 |
Why?
|
| Motor Activity | 2 | 2017 | 331 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1391 | 0.220 |
Why?
|
| Risk Factors | 4 | 2017 | 2421 | 0.210 |
Why?
|
| Prone Position | 1 | 2003 | 35 | 0.210 |
Why?
|
| Oxygen | 1 | 2003 | 81 | 0.200 |
Why?
|
| Risk | 2 | 2020 | 208 | 0.200 |
Why?
|
| Maternal Age | 2 | 2019 | 15 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 133 | 0.200 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 85 | 0.190 |
Why?
|
| Child | 3 | 2022 | 1423 | 0.190 |
Why?
|
| Young Adult | 5 | 2019 | 2100 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 12 | 0.180 |
Why?
|
| Arachidonic Acid | 1 | 2021 | 15 | 0.180 |
Why?
|
| Directive Counseling | 2 | 2019 | 14 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2021 | 67 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 15 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2020 | 18 | 0.180 |
Why?
|
| Premature Birth | 1 | 2020 | 11 | 0.180 |
Why?
|
| Time Factors | 3 | 2018 | 1497 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 33 | 0.170 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 137 | 0.170 |
Why?
|
| Tissue Donors | 1 | 2021 | 79 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 329 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2020 | 75 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 321 | 0.170 |
Why?
|
| Linear Models | 2 | 2017 | 255 | 0.170 |
Why?
|
| Sleep | 1 | 2003 | 355 | 0.170 |
Why?
|
| Contraception Behavior | 1 | 2019 | 5 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 112 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 334 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 196 | 0.160 |
Why?
|
| Logistic Models | 2 | 2017 | 397 | 0.160 |
Why?
|
| Infant Care | 2 | 2016 | 19 | 0.160 |
Why?
|
| Nutritional Support | 1 | 2018 | 25 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 68 | 0.150 |
Why?
|
| Food, Fortified | 1 | 2018 | 9 | 0.150 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 7 | 0.150 |
Why?
|
| Chicago | 3 | 2016 | 941 | 0.150 |
Why?
|
| Cognition | 2 | 2017 | 1371 | 0.150 |
Why?
|
| Energy Intake | 1 | 2018 | 83 | 0.150 |
Why?
|
| Length of Stay | 1 | 2020 | 328 | 0.150 |
Why?
|
| Nod1 Signaling Adaptor Protein | 1 | 2017 | 2 | 0.140 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 7 | 0.140 |
Why?
|
| Protective Factors | 1 | 2017 | 27 | 0.140 |
Why?
|
| Probiotics | 1 | 2017 | 19 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 55 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2017 | 66 | 0.140 |
Why?
|
| Oligosaccharides | 1 | 2017 | 18 | 0.140 |
Why?
|
| Peer Group | 1 | 2017 | 40 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 41 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1868 | 0.140 |
Why?
|
| Qualitative Research | 1 | 2017 | 124 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 135 | 0.130 |
Why?
|
| Bacteremia | 1 | 2017 | 101 | 0.130 |
Why?
|
| Anemia | 1 | 2017 | 94 | 0.130 |
Why?
|
| Return to Work | 1 | 2016 | 65 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 44 | 0.130 |
Why?
|
| Phylogeny | 1 | 2016 | 48 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 55 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 47 | 0.130 |
Why?
|
| Illinois | 1 | 2016 | 247 | 0.130 |
Why?
|
| Feces | 1 | 2016 | 109 | 0.120 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sepsis | 1 | 2017 | 144 | 0.120 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 15 | 0.120 |
Why?
|
| Cost Savings | 1 | 2015 | 36 | 0.120 |
Why?
|
| Retinopathy of Prematurity | 1 | 2014 | 7 | 0.110 |
Why?
|
| Adolescent | 2 | 2017 | 2324 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2013 | 7 | 0.110 |
Why?
|
| Hospital Costs | 1 | 2013 | 64 | 0.100 |
Why?
|
| Direct Service Costs | 1 | 2012 | 4 | 0.100 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Codon, Terminator | 1 | 2011 | 3 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 2 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 600 | 0.090 |
Why?
|
| Fluconazole | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cultured Milk Products | 1 | 2009 | 3 | 0.090 |
Why?
|
| Milk | 1 | 2009 | 15 | 0.090 |
Why?
|
| Mycoses | 1 | 2010 | 23 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 32 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2010 | 44 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 440 | 0.080 |
Why?
|
| Animals | 4 | 2020 | 3798 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 382 | 0.070 |
Why?
|
| Biomarkers | 2 | 2020 | 601 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2005 | 82 | 0.060 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2003 | 7 | 0.050 |
Why?
|
| Blood Gas Analysis | 1 | 2003 | 8 | 0.050 |
Why?
|
| Bedding and Linens | 1 | 2003 | 6 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 9 | 0.050 |
Why?
|
| Tidal Volume | 1 | 2003 | 13 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2003 | 29 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2003 | 20 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 36 | 0.050 |
Why?
|
| Sudden Infant Death | 1 | 2003 | 37 | 0.050 |
Why?
|
| Polysomnography | 1 | 2003 | 85 | 0.050 |
Why?
|
| Face | 1 | 2003 | 23 | 0.050 |
Why?
|
| Ranibizumab | 1 | 2020 | 2 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2020 | 3 | 0.050 |
Why?
|
| Choroid Diseases | 1 | 2020 | 3 | 0.050 |
Why?
|
| Retinal Diseases | 1 | 2020 | 5 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2020 | 21 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 12 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 31 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 72 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 424 | 0.040 |
Why?
|
| Intention | 1 | 2019 | 23 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 466 | 0.040 |
Why?
|
| Oceania | 1 | 2018 | 3 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 10 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 11 | 0.040 |
Why?
|
| North America | 1 | 2018 | 43 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 67 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 11 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 25 | 0.040 |
Why?
|
| Obesity | 1 | 2021 | 322 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 358 | 0.040 |
Why?
|
| Weight Gain | 1 | 2018 | 66 | 0.040 |
Why?
|
| Income | 1 | 2018 | 78 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2017 | 60 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 146 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 274 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 308 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 9 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2015 | 11 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 19 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 118 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 211 | 0.030 |
Why?
|
| Cell Line | 1 | 2015 | 279 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 80 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 676 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 58 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 192 | 0.030 |
Why?
|
| Inflammation | 1 | 2015 | 288 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2012 | 53 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 161 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 157 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2011 | 100 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 17 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 103 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 1467 | 0.020 |
Why?
|
| Cholestasis | 1 | 2010 | 10 | 0.020 |
Why?
|
| Colostrum | 1 | 2010 | 5 | 0.020 |
Why?
|
| Candidiasis | 1 | 2010 | 22 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 448 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 992 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 824 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 3619 | 0.010 |
Why?
|